GT Biopharma Inc

GT Biopharma (NASDAQ: GTBP) is a clinical-stage immuno-oncology company focused on developing TriKE® NK cell engager therapies. These innovative, off-the-shelf drug candidates are designed to activate natural killer cells against blood cancers, solid tumors, and autoimmune diseases, while overcoming some of the limitations of CAR-T therapy. 

The company’s pipeline includes GTB-3650 in a first-in-human Phase 1 clinical trial for AML and MDS, GTB-5550 advancing toward trials in B7H3-positive solid tumors, and GTB-7550 in preclinical development for CD19-related lymphoid cancers and autoimmune disease.